Explain the difference between organic EBITDA growth, acquired EBITDA at cost, and multiple arbitrage, and why an LP would want a platform's return decomposed across all three.

What the interviewer is actually testing

Add-on strategy questions test whether you understand that private equity returns increasingly come from sourcing and execution skill (finding and integrating add-ons) as much as from operational improvement of a single asset. The baseline test is arithmetic: given a platform multiple and an add-on multiple, can you compute the instant re-rating gain? Almost every candidate can do this once shown the formula; the differentiation is in the why and the risk.

A strong candidate explains why smaller businesses trade at lower multiples in the first place: thinner management, customer concentration, less audited financials, smaller buyer pool, private-equity-fund-size constraints (a $2B fund can't efficiently deploy into a $10M-EBITDA deal on its own, but can via an add-on), rather than treating the multiple gap as an unexplained given. This shows you understand valuation, not just the mechanic.

Interviewers also probe whether you can separate real value creation from arithmetic re-rating. The strongest signal a candidate can give is volunteering that multiple arbitrage is not "free" in a risk-adjusted sense: it depends on the exit buyer paying the platform multiple for the whole combined entity, including the bolted-on EBITDA, which is not guaranteed if integration has been messy or if the platform is perceived as a rollup rather than an organically excellent business. Candidates who can discuss integration risk, synergy realization risk, and multiple compression risk in the same breath as the upside are showing PE-associate-level fluency, which is exactly the bar at Qatalyst, PWP, and the megafund-adjacent boutiques.

Finally, expect a numerical curveball combining add-on economics with financing: how the deal is funded (debt vs. equity) changes the IRR impact even though the EV-level arbitrage math is unchanged.

Common traps

Trap 1: Confusing multiple arbitrage with organic growth. Candidates describe a platform's EBITDA growth from $50M to $90M as "the business performed well," without separating how much of the $40M came from add-ons bought below the platform multiple versus true organic improvement.

Say it out loud: "I'd split that $40M of EBITDA growth into organic and acquired: if $25M came from add-ons, that's a sourcing and integration story, not purely an operational one, and it should be valued and underwritten differently."

Trap 2: Assuming the arbitrage is risk-free or permanent. The re-rating gain only becomes real cash at exit, and only if the exit buyer applies the same (or higher) multiple to the combined entity. Some buyers discount rollups for integration and quality-of-earnings risk.

Say it out loud: "The arbitrage is a paper gain until exit: if buyers perceive the platform as a rollup with integration risk, they may apply a lower multiple than the platform's standalone rating, eroding some or all of the arbitrage."

Trap 3: Ignoring integration costs and synergy realization risk. Candidates assume 100% of projected synergies show up on schedule. In practice, synergies from eliminating duplicate functions often take 12–24 months and rarely fully materialize.

Say it out loud: "I'd underwrite the add-on on standalone economics first and treat synergies as upside, phased in over time (not day-one EBITDA) since realization risk and integration costs are real and often underestimated."

Trap 4: Forgetting how the add-on is financed when assessing IRR impact. Two add-ons with identical EV-level arbitrage produce very different sponsor IRRs depending on whether they're funded with new sponsor equity or with debt against the combined entity's cash flow.

Say it out loud: "The multiple arbitrage math is the same either way, but if this add-on is funded mostly with debt off the platform's existing credit facility, the sponsor's incremental equity check (and therefore the IRR impact) is much smaller than if fresh equity were required."

Trap 5: Treating all add-ons as equally 'cheap.' Not every bolt-on trades meaningfully below the platform. A well-run, scaled competitor might command 8.5x against a 10x platform (real but modest arbitrage) versus a distressed owner-operator at 5x. Candidates sometimes assume a flat, generous multiple gap without justifying it.

Say it out loud: "The size of the arbitrage depends on how much smaller and less institutional the target is: I wouldn't assume a uniform 3–4 turn gap without knowing the target's scale, growth, and quality relative to the platform."

Trap 6: Missing that heavy roll-up strategies can face 'deal fatigue' or antitrust/HSR scrutiny at scale. As a platform does its 10th, 15th add-on in a niche, regulatory scrutiny (especially in healthcare services in the US) and diminishing target supply become real constraints on the strategy's runway.

Say it out loud: "A buy-and-build strategy has a finite runway: as the platform consolidates a niche, remaining targets shrink in number and quality, and regulators increasingly scrutinize serial acquirers in sectors like healthcare, so I'd model the strategy's addressable pipeline explicitly rather than assuming add-ons indefinitely."